Radiotherapy in lymph node-positive prostate cancer patients - A potential cure? Single institutional experience regarding outcome and side effects

Frontiers of Radiation Therapy and Oncology

Volumn 41, Issue , 2008, Pages 68-76

  Goldner, G ^a   Potter R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; BLOOD; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 49449083756     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000139880     Document Type: Conference Paper

References (10)

1. DeKernion JB, Neuwirth H, Stein A, Dorey F, Stenzl A, Hannah J, Blyth B: Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J Urol 1990;144:700-703.
2. Steinberg GD, Epstein JI, Piantadosi S, Walsh PC: Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974-1987. J Urol 1990;144:1425-1432.
3. Hanks GE, Buzydlowski J, Sause WT, Emami B, Rubin P, Parsons JA, Russell AH, Byhardt RW, Earle JD, Pilepich MV: Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06. Int J Radiat Oncol Biol Phys 1998;40:765-768.
4. Wiegel T, Bressel M: Influence of the extent of nodal involvement on the outcome in stage D1 prostate cancer. Radiat Oncol Invest 1994;2:144-151.
5. Sands E, Pollack A, Zagars GK: Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. Int J Radiat Oncol Biol Phys 1995;31:13-19.
6. Gervasi LA, Mata J, Easley JD, Wilbanks JH, Seale-Hawkins C, Carlton CE Jr, Scardino PT: Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989;142:332-336.
7. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997;37:1035-1041.
8. Kramer SA, Kline WA Jr, Farham R, Carson CC, Cox EB, Hinshaw W, Paulson DF: Prognosis of patients with stage D1 prostatic adenocarcinoma. J Urol 1981;125:817-819.
9. Whittington R, Malkowicz SB, Barnes MM, Broderick GA, van Arsdalen K, Dougherty MJ, Wein AJ: Combined hormonal and radiation therapy for lymph node-positive prostate cancer. Urology 1995;46:213-219.
10. Roach M 3rd, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, Thomas CR Jr, Shipley WU: Whole-pelvis, 'mini-pelvis', or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 2006;66:647-653.